For all his faults, and there were many, at least
Post# of 151259
Jay’s Ninja-like approach, where nobody outside our group and a few scientists have any clue what Leronlimab can do, is why our share price is sitting perilously close to a return to the teens.
I’d like a CEO with Jay’s integrity and connections, coupled with someone who moves faster, communicates more, and has a bit of Nader’s showmanship.

